Abstract
Warfarin-related intracerebral hemorrhage carries a particularly high risk of neurologic deterioration and death because of a high rate of hematoma expansion of about 50%. Novel oral anticoagulants (NOACs)--apixaban, dabigatran, and rivaroxaban--have a significantly smaller risk of intracerebral hemorrhage (ICH). However, two facts make this situation complicated: First, the risk of hematoma expansion is unknown for NOACs. Second, there is no specific antidote for neither of the NOACs. We present a case that suggests that hematoma expansion may occur after NOAC-related ICH.
Keywords:
Intracerebral hemorrhage; anticoagulant; atrial fibrillation; stroke.
Copyright © 2014 National Stroke Association. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Administration, Oral
-
Aged
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects*
-
Atrial Fibrillation / complications
-
Atrial Fibrillation / diagnosis
-
Atrial Fibrillation / drug therapy*
-
Benzimidazoles / administration & dosage
-
Benzimidazoles / adverse effects*
-
Cerebral Hemorrhage / chemically induced*
-
Cerebral Hemorrhage / diagnosis
-
Dabigatran
-
Fatal Outcome
-
Hematoma / chemically induced*
-
Hematoma / diagnosis
-
Humans
-
Male
-
Risk Factors
-
Stroke / diagnosis
-
Stroke / etiology
-
Stroke / prevention & control*
-
Time Factors
-
Tomography, X-Ray Computed
-
Treatment Outcome
-
beta-Alanine / administration & dosage
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives*
Substances
-
Anticoagulants
-
Benzimidazoles
-
beta-Alanine
-
Dabigatran